Get the Stockscreener App
92.50
1.14%
1.04
After Hours:
92.50
Biontech Se Adr stock is traded at $92.50, with a volume of 2.69M.
It is up +1.14% in the last 24 hours and down -8.80% over the past month.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
See More
Previous Close:
$91.46
Open:
$91.79
24h Volume:
2.69M
Relative Volume:
2.75
Market Cap:
$22.24B
Revenue:
$3.53B
Net Income/Loss:
$-632.88M
P/E Ratio:
-35.16
EPS:
-2.631
Net Cash Flow:
$-588.37M
1W Performance:
-2.44%
1M Performance:
-8.80%
6M Performance:
-11.40%
1Y Performance:
-16.92%
1-Day Range:
$91.54
$93.32
1-Week Range:
$91.11
$94.75
52-Week Range:
$81.20
$129.27
Biontech Se Adr Stock (BNTX) Company Profile
Compare BNTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
92.50 | 21.99B | 3.53B | -632.88M | -588.37M | -2.631 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.20 | 113.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
767.96 | 78.69B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.23 | 52.32B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.99 | 52.15B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.84 | 35.52B | 447.02M | -1.18B | -906.14M | -6.1812 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Reiterated | H.C. Wainwright | Buy |
| May-29-25 | Initiated | Goldman | Neutral |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Jan-10-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Reiterated | BMO Capital Markets | Outperform |
| Nov-19-24 | Initiated | Berenberg | Buy |
| Nov-19-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-08-24 | Upgrade | Goldman | Neutral → Buy |
| Sep-24-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-17-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-16-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-07-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-02-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-14-24 | Initiated | Evercore ISI | In-line |
| Feb-23-24 | Initiated | BMO Capital Markets | Outperform |
| Jan-05-24 | Initiated | Oppenheimer | Perform |
| Dec-01-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-16-23 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-17-23 | Upgrade | Redburn | Neutral → Buy |
| Dec-15-22 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-17-22 | Initiated | Cowen | Market Perform |
| Jul-13-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Dec-16-21 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-22-21 | Initiated | Deutsche Bank | Hold |
| Oct-07-21 | Initiated | Jefferies | Hold |
| Aug-11-21 | Upgrade | Bryan Garnier | Neutral → Buy |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jun-16-21 | Downgrade | Redburn | Neutral → Sell |
| May-18-21 | Initiated | Goldman | Neutral |
| May-11-21 | Downgrade | Bryan Garnier | Buy → Neutral |
| Dec-01-20 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-03-20 | Resumed | Berenberg | Buy |
| Jul-21-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-30-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-19-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-28-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-18-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-09-20 | Initiated | H.C. Wainwright | Neutral |
| Jan-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jan-22-20 | Downgrade | UBS | Buy → Neutral |
| Nov-05-19 | Initiated | Wolfe Research | Outperform |
| Nov-04-19 | Initiated | Berenberg | Buy |
| Nov-04-19 | Initiated | BofA/Merrill | Buy |
| Nov-04-19 | Initiated | Canaccord Genuity | Buy |
| Nov-04-19 | Initiated | JP Morgan | Overweight |
| Nov-04-19 | Initiated | SVB Leerink | Outperform |
| Nov-04-19 | Initiated | UBS | Buy |
View All
Biontech Se Adr Stock (BNTX) Latest News
New Pumitamig Kidney Cancer Trial Adds Long-Term Optionality for Bristol-Myers Squibb and BioNTech - TipRanks
BMY and BNTX Advance New Immunotherapy Bet in First-Line Liver Cancer With ROSETTA HCC-206 - TipRanks
Research Analysts’ Weekly Ratings Updates for BioNTech (BNTX) - Defense World
Nanobiotechnology Market to Hit USD 420.2 Billion by 2034, Fueled by 2025 Traffic Growth and Strategic Material & Product Innovations - GlobeNewswire Inc.
Hudson Bay Capital Management LP Sells 15,000 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
FY2025 EPS Estimates for BioNTech Decreased by HC Wainwright - MarketBeat
Gilder Gagnon Howe & Co. LLC Has $71.08 Million Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Bellevue Group AG Raises Stake in BioNTech SE Sponsored ADR $BNTX - MarketBeat
HC Wainwright Has Positive Estimate for BioNTech Q4 Earnings - Defense World
FDA Weighs Black Box Warning For COVID Vaccines, Experts Push Back - Sahm
BioNTech SE’s New Study on PM8002: A Potential Game-Changer in Colorectal Cancer Treatment - MSN
Research Analysts Set Expectations for BioNTech Q4 Earnings - MarketBeat
Berenberg Bank Issues Positive Forecast for BioNTech (NASDAQ:BNTX) Stock Price - Defense World
BioNTech SE (BNTX) is a Buy on Lung Cancer Treatment Prospects: Clear Street - Finviz
Invesco Ltd. Buys 35,958 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Amundi Lowers Stake in BioNTech SE Sponsored ADR $BNTX - Defense World
Altrinsic Global Advisors LLC Sells 123,995 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
ETFs investiert in BioNTech SE Sponsored ADR-AktienTradingView - TradingView - Alle Märkte im Blick
Dymon Asia Capital Singapore PTE. LTD. Makes New $1.86 Million Investment in BioNTech SE Sponsored ADR $BNTX - MarketBeat
First Trust Advisors LP Has $35.28 Million Holdings in BioNTech SE Sponsored ADR $BNTX - Defense World
BioNTech's Oncology Pipeline Gains Momentum with Key Clinical Data () - aktiencheck.de
BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart - Seeking Alpha
BioNTech Shares Gain on Promising Oncology Data and Acquisition Milestone () - aktiencheck.de
DoorDash Upgraded, Microsoft Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BioNTech stock rises after promising lung cancer drug shows survival benefit By Investing.com - Investing.com South Africa
BioNTech stock rises after promising lung cancer drug shows survival benefit - Investing.com
Temasek Holdings Private Ltd Lowers Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
25,780 Shares in BioNTech SE Sponsored ADR $BNTX Bought by Bollard Group LLC - MarketBeat
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Dodge & Cox Invests $93.42 Million in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech’s (BNTX) “Buy” Rating Reaffirmed at Jefferies Financial Group - Defense World
Regulatory Storm Hits BioNTech as FDA Memo Sparks Sector-Wide Anxiety () - aktiencheck.de
Vaccine Stocks Fall After FDA Plans to Impose Stricter Vaccine Rules - Nasdaq
Scotia Capital Inc. Cuts Stock Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Validea's Top Health Care Stocks Based On Benjamin Graham12/1/2025 - Nasdaq
Groupama Asset Managment Buys 26,681 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Employees Retirement System of Texas Has $1.69 Million Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Legal & General Group Plc Boosts Stock Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Aristides Capital LLC Purchases 2,826 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech SE ADR Rises 3.0%, Outperforms Market - 富途牛牛
Edmond DE Rothschild Holding S.A. Raises Stock Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech’s acquisition of CureVac nears completion as offer deadline approaches - Investing.com
BioNTech SE Sponsored ADR $BNTX Shares Purchased by CenterBook Partners LP - MarketBeat
AXQ Capital LP Acquires 1,073 Shares of Strategy Inc $MSTR - Defense World
Bank Julius Baer & Co. Ltd Zurich Lowers Stock Holdings in BioNTech SE Sponsored ADR $BNTX - Defense World
Allworth Financial LP Grows Stake in BioNTech SE Sponsored ADR $BNTX - Defense World
Primecap Management Co. CA Sells 44,959 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Pfizer Is Giving Up on BioNTech. Should You Ditch BNTX Stock Now Too? - Barchart.com
BioNTech Faces Strategic Crossroads as Pfizer Reduces Stake () - aktiencheck.de
Total debt per share of BioNTech SE Sponsored ADR – BER:22UA - TradingView
SG Americas Securities LLC Acquires 51,792 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Biontech Se Adr Stock (BNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):